Axsome Therapeutics has given long term holders a powerful ride, yet with the stock at US$143.45 after a choppy few months, the real question is how well that price lines up with the sales the business is generating. For anyone considering the shares today, the focus is less on the past swings and more on whether Axsome's current market value is grounded in its revenue base.
- Over the past 5 years the stock has returned 251.2%. That puts a lot of weight on whether its sales can sustain the kind of expectations now embedded in the share price.
- The company’s model depends heavily on turning its portfolio into steady product revenue, so the pace and durability of those sales can shape how much investors are willing to pay for each dollar of top line.
- Your read on Axsome Therapeutics is one view; the desks covering it have another. See what analysts think Axsome Therapeutics's shares could be worth.
The stock's next move may depend on whether Axsome Therapeutics' current share price is appropriately supported by its sales.
If you are weighing whether Axsome Therapeutics' current US$143.45 share price lines up with its sales, it can help to compare that revenue story with 30 high quality undervalued stocks.
Is Axsome Therapeutics Still Cheap on Sales?
P/S fits Axsome Therapeutics because the story still leans heavily on how much revenue its pipeline can turn into, rather than on current profits. At roughly 9.7x P/S, the stock trades at more than double the wider pharmaceuticals industry average of about 4.5x, which signals that investors are willing to pay a premium for each dollar of Axsome's sales.
Compared with closer peers, where the average P/S is about 9.4x, Axsome's multiple is only slightly higher, which puts the valuation more in line with specialist rivals than with the broader sector. The fair multiple implied by its own profile of growth expectations, margins and risk sits above the current 9.7x P/S, which indicates that this framework treats the stock as undervalued on revenue alone, even after the strong share price run. Explore the numbers behind Axsome Therapeutics's P/S valuation.
The Axsome Therapeutics Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St extend the Axsome Therapeutics story beyond the current P/S puzzle by spelling out which future paths for growth, margins and earnings would leave the stock looking meaningfully overvalued or undervalued compared with today's share price. Each scenario links its valuation number to a clear view on where revenues, profitability and risk could head next so you can revisit those assumptions as fresh information comes through.
One of the top community narratives on Axsome Therapeutics: 49% undervalued
"Axsome's portfolio is expanding with the launch of SYMBRAVO for migraine and ongoing robust growth of Auvelity and Sunosi..."
Discover why this Narrative puts Axsome Therapeutics at 49% undervalued.
One more Axsome Therapeutics checkpoint that sits beyond the current share price
Sales based gauges only tell part of the story, because professional coverage also sketches where this business might be a few years from now, which gives you another lens to compare with today’s valuation. Explore where analysts expect Axsome Therapeutics to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com